Information Provided By:
Fly News Breaks for May 16, 2018
FATE
May 16, 2018 | 10:13 EDT
Piper Jaffray analyst Edward Tenthoff says Fate Therapeutics' licensing agreement with Memorial Sloan Kettering Cancer Center "significantly" expands the engineering optionality of its PSC cell therapies. The first iPSC NK cell FT500 will enter the clinic this year and FT819 next year, Tenthoff tells investors in a research note. He points out that three Phase I studies for NK100 showed early safety and signs of activity after a single infusion in acute myeloid leukemi and ovarian cancer. The analyst anticipates additional Phase I NK100 data this year and sees Fate as a potential acquisition target. He reiterates an Overweight rating on the shares with a $20 price target.